Immunosuppressant Management in Renal Transplant Patients with COVID-19 | Zendy

Elham Ahmadian | Zendy; Sepideh Zununi Vahed | Zendy; Shakar Mammadova | Zendy; Sima Abediazar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immunosuppressant Management in Renal Transplant Patients with COVID-19

Author(s) -

Elham Ahmadian,

Sepideh Zununi Vahed,

Shakar Mammadova,

Sima Abediazar

Publication year - 2021

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2021/9318725

Subject(s) - immunosuppression , medicine , pandemic , intensive care medicine , covid-19 , comorbidity , disease , kidney transplantation , immunology , transplantation , infectious disease (medical specialty) , virology , outbreak

The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should be considered immunocompromised hosts since a potential risk for infection, comorbidity, and immunosuppression exposure exists. Additionally, the management of immunosuppressive agents in KDRs remains challenging. Potential drug interactions with immunosuppressive treatment escalated the risk of unwanted side effects. In this review, we aimed to attain an augmented awareness and improved management immunosuppressant for COVID-19 KDRs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research